Evidence mapPaperPMID 39063013Full record

ReviewInternational journal of molecular sciences2024

Dementia after Ischemic Stroke, from Molecular Biomarkers to Therapeutic Options.

Vikalpa Dammavalam, Deborah Rupert, Marcos Lanio, Zhaosheng Jin, Neil Nadkarni, Stella E Tsirka, Sergio D Bergese

Abstract readReview
In one paragraph

Review in International journal of molecular sciences, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 11 papers.

0numbers the graph read from it
0cells of the map it votes in
11citing papers in PubMed
field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

11 citing papers in PubMed.

  1. Article
  2. Article
  3. Article
  4. Review
  5. Article
  6. Review
  7. Review
  8. Review
  9. Review
  10. Article
  11. Alterations ofCurrent Alzheimer research · 2025
    Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors.

Vikalpa DammavalamDepartment of Neurology, Stony Brook University Hospital, Stony Brook, NY 11794, USA.
Deborah RupertRenaissance School of Medicine, Stony Brook University, Stony Brook, NY 11794, USA.
Marcos LanioDepartment of Neurology, Stony Brook University Hospital, Stony Brook, NY 11794, USA.ORCID 0000-0003-3000-1592
Zhaosheng JinDepartment of Anesthesiology, Stony Brook University Hospital, Stony Brook, NY 11794, USA.ORCID 0000-0002-2495-7048
Neil NadkarniDepartment of Neurology, Stony Brook University Hospital, Stony Brook, NY 11794, USA.ORCID 0000-0003-3485-1519
Stella E TsirkaDepartment of Pharmacological Sciences, Renaissance School of Medicine, Stony Brook University, Stony Brook, NY 11794, USA.ORCID 0000-0003-0022-1770
Sergio D BergeseDepartment of Neurology, Stony Brook University Hospital, Stony Brook, NY 11794, USA.ORCID 0000-0001-5641-5908

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Ischemic stroke is a leading cause of disability worldwide. While much of post-stroke recovery is focused on physical rehabilitation, post-stroke dementia (PSD) is also a significant contributor to poor functional outcomes. Predictive tools to identify stroke survivors at risk for the development of PSD are limited to brief screening cognitive tests. Emerging biochemical, genetic, and neuroimaging biomarkers are being investigated in an effort to unveil better indicators of PSD. Additionally, acetylcholinesterase inhibitors, NMDA receptor antagonists, dopamine receptor agonists, antidepressants, and cognitive rehabilitation are current therapeutic options for PSD. Focusing on the chronic sequelae of stroke that impair neuroplasticity highlights the need for continued investigative trials to better assess functional outcomes in treatments targeted for PSD.

Indexed as

BiomarkersDementiaIschemic StrokeHumansBiomarkersbiomarkerscognitive declinedementiaischemic strokenovel therapy

Identifiers

PMID39063013
PMCPMC11276729

What Socratic holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.